Virpax Pharmaceuticals, Inc.
DelistedCIK 1708331fmd_1ZVHQ755DX3Q6ASE7Q668MVW6FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2024, 20 periods
Latest annual · FY2024
Millions- Operating income
- (12)
- Net income
- (12)
Latest quarter · Q4 FY2024
Millions- Operating income
- (3)
- Net income
- (3)
Virpax Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$12.1 million | -$15.7 million | 10-K 2025-03-03 · proof | |
| Net income | -$12.1 million | -$15.2 million | 10-K 2025-03-03 · proof | |
| Cash from operating activities | -$16.7 million | -$9.9 million | 10-K 2025-03-03 · proof | |
| Total assets | $1.6 million | $9.6 million | -83.8% | 10-K 2025-03-03 · proof |
| Total liabilities | $2.5 million | $7.7 million | -67.9% | 10-K 2025-03-03 · proof |
| Cash and cash equivalents | $1.5 million | $9.1 million | -83.4% | 10-K 2025-03-03 · proof |
- What was Virpax Pharmaceuticals, Inc.'s operating income in fiscal 2024?
- Virpax Pharmaceuticals, Inc. reported operating income of -$12.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$15.7 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was Virpax Pharmaceuticals, Inc.'s net income in fiscal 2024?
- Virpax Pharmaceuticals, Inc. reported net income of -$12.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$15.2 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was Virpax Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2024?
- Virpax Pharmaceuticals, Inc. reported cash from operating activities of -$16.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$9.9 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Virpax Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2024, Virpax Pharmaceuticals, Inc. reported total assets of $1.6 million, against $9.6 million a year earlier (-83.8%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Virpax Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2024, Virpax Pharmaceuticals, Inc. reported total liabilities of $2.5 million, against $7.7 million a year earlier (-67.9%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are Virpax Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Virpax Pharmaceuticals, Inc. reported cash and cash equivalents of $1.5 million, against $9.1 million a year earlier (-83.4%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1708331&period_type=annual&limit=5"Information only, not investment advice.